For the quarter ending 2026-03-31, TXMD had $936K increase in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| income (loss) from continuing operations before income taxes | 103 | - | - | - |
| Impairment of long-lived assets (note 4) | - | - | - | 0 |
| Net income (loss) from continuing operations | 103 | -612 | 50 | -91 |
| Depreciation and amortization | - | 97 | 96 | 191 |
| Write-off and impairment of patents | - | 57 | 31 | 88 |
| Depreciation and amortization | 94 | - | - | - |
| Share-based compensation costs | 2 | 51 | 0 | 24 |
| Other | - | - | 217 | 370 |
| Amortization of right of use assets | 231 | 809 | - | - |
| Other assets | -881 | -619 | -529 | -872 |
| Prepaid and other current assets | 196 | -389 | -4 | 192 |
| Accounts payable | -340 | 114 | -87 | 92 |
| Accrued expenses and other current liabilities | 434 | -237 | 425 | 84 |
| Lease liabilities | -266 | -326 | -307 | -445 |
| Other non-current liabilities | 1 | 1 | 41 | 87 |
| Total adjustments | 841 | 987 | 949 | 1,171 |
| Net cash provided by continuing operating activities | 944 | 375 | 999 | 1,080 |
| Net cash used in operating activities | -8 | -7 | 47 | -70 |
| Net increase in cash | 936 | 368 | 1,046 | 1,010 |
| Cash and cash equivalents - continuing operations, beginning of period | 7,483 | 7,115 | 5,059 | - |
| Total cash and cash equivalents, end of period | 8,419 | 7,483 | 7,115 | - |
TherapeuticsMD, Inc. (TXMD)
TherapeuticsMD, Inc. (TXMD)